Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Innovative Medical |
---|---|
Information provided by: | Innovative Medical |
ClinicalTrials.gov Identifier: | NCT00347503 |
Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.
Condition | Intervention | Phase |
---|---|---|
Cataract |
Drug: ketorolac 0.4%, bromfenac 0.09% |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment |
Official Title: | Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | B2601 |
Study First Received: | June 29, 2006 |
Last Updated: | July 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00347503 |
Health Authority: | United States: Institutional Review Board |
Dinoprostone Bromfenac Eye Diseases Cataract |
Ketorolac Lens Diseases Ketorolac Tromethamine |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |